Advances of peroxisome proliferator-activated receptors agonists in the treatment of non-alcoholic steatohepatitis

倪佳英,苏青

DOI: https://doi.org/10.3760/cma.j.cn121383-20210407-04013

2022-01-01

International Journal of Endocrinology and Metabolism

Abstract:Non-alcoholic steatohepatitis (NASH) is the severer subtype of non-alcoholic fatty liver disease (NAFLD). It is characterized by hepatic steatosis, inflammation and fibrosis. Peroxisome proliferator-activated receptors (PPARs) are a class of ligand-activated nuclear transcription factors, including PPARα, PPARβ/δ, and PPARγ. As important regulators of lipid metabolism, glucose homeostasis, and inflammation, PPARs have become potential targets for NASH therapy. In recent years, more and more studies have shown that PPARs agonists can improve NASH histology in animal experiments, showing great advantages. Evidence of PPARs agonists in clinical trials has also sprouted, which make them a promising agent in the treatment of NAFLD/NASH.